Has Ryan Abel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,199 in general payments to Ryan Abel, MD across 341 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ryan Abel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ryan Abel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ryan Abel, MD

Radiation Oncology · Owensboro, KYNPI 1437385770

Payments from drug & device makers

$6,199in general payments, 2019–2025

Across 341 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$738
Merck$464
Pfizer$416
AstraZeneca$302
Daiichi Sankyo Inc.$293
Johnson & Johnson$293
plus $4K from 54 others

What the payments were for

Food & beverage$6,01897%
Education$1813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	52	$738
Merck	28	$464
Pfizer	22	$416
AstraZeneca(2 entities)	14	$302
Daiichi Sankyo Inc.	16	$293
Johnson & Johnson	18	$293
Seagen Inc.	12	$256
Genentech USA, Inc.	13	$208
Amgen	8	$184
Novocure Inc.	11	$183
Takeda Pharmaceuticals U.S.A., Inc.	9	$171
Incyte Corporation	8	$160
Sanofi	8	$150
Tempus AI, Inc	5	$142
Regeneron Healthcare Solutions, Inc.	8	$138
Eisai Inc.	7	$138
Astellas Pharma US Inc	6	$108
Lilly USA, LLC	7	$105
ADC Therapeutics America, Inc.	6	$104
Boston Scientific	2	$98
Sumitomo Pharma America, Inc.	4	$89
Cumberland Pharmaceuticals, Inc.	4	$80
Gilead	3	$68
Beigene USA, Inc.	4	$66
Reflexion Medical, Inc.	2	$63
Genmab U.S., Inc.	2	$59
Mirati Therapeutics, Inc.	3	$58
AbbVie	3	$58
Bayer	3	$54
Tersera Therapeutics LLC	3	$51
Sobi, Inc	2	$49
Iovance Biotherapeutics, Inc.	4	$49
Puma Biotechnology, Inc.	3	$48
Sun Pharmaceutical Industries Inc.	2	$45
Blue Earth Diagnostics	2	$45
Celltrion USA Inc.	2	$40
Monteris Medical Corporation	1	$37
Accuray Incorporated	2	$36
Coherus Oncology, Inc.	2	$35
Blueprint Medicines Corporation	2	$35
Pharmacosmos Therapeutics Inc.	2	$34
AVEO Pharmaceuticals, Inc.	2	$34
Myriad Genetic Laboratories, Inc.	2	$32
Tactile Systems Technology Inc	1	$31
Stemline Therapeutics Inc.	2	$30
Beone Medicines USA, Inc.	2	$30
Pharmacyclics LLC, An Abbvie Company	2	$28
Progenics Pharmaceuticals, Inc.	1	$24
Bioprotect Medical, Inc.	1	$22
Accord Healthcare, Inc.	1	$22
Fennec Pharmaceuticals, Inc.	1	$21
Medtronic	1	$18
Array Biopharma Inc	1	$18
Syndax Pharmaceuticals, Inc.	1	$17
Kyowa Kirin, Inc.	1	$17
G1 Therapeutics, Inc.	1	$17
Caris MPI, Inc.	1	$17
Karyopharm Therapeutics Inc.	1	$16
Siemens Medical Solutions USA, Inc.	1	$16
Foundation Medicine, Inc.	1	$15

How this compares

$6,199 in reported general payments places this provider in the 85th percentile of 81 radiation oncology providers in Kentucky.

See all radiation oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$406,182

Medicare patients

326

Services billed

4,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sucralfate	15	$1,303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	43	$994
Pentoxifylline	17	$508
Memantine Hcl	18	$368
Tamsulosin Hcl	37	$339
Morphine Sulfate ErMorphine Sulfate	11	$234
Ondansetron OdtOndansetron	15	$230
SsdSilver Sulfadiazine	12	$112

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Owensboro

Patrick NewburyOwensboro$1K
Tristan BrionesOwensboro$201
Eddy YangLexington$1.2M
Jonathan FeddockLexington$290K
Neal DunlapLouisville$286K
Aaron SpaldingLouisville$174K
Shiao WooLouisville$67K
Adrianna MastersLouisville$34K
Parag SevakLouisville$23K
Elyn WangPikeville$21K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →